Global Blood Therapeutics (GBT) Data 'Exceeded Our High Expectations' - Cowen

Cowen analyst Ritu Baral reiterated an Outperform rating and $80 price target on Global Blood Therapeutics (NASDAQ: GBT) as the company is presenting first 90-day SCD tx data of 'left shifter' GBT today at EHA.

"We are highly encouraged by not just the magnitude of the median Hb increase (1.1g/dL), but also the consistency of hemolysis marker improvement and excellent safety," the analyst said. "While datasets released at EHA were not without some quirks, likely due to small patient numbers, overall data exceeded our high expectations."

For an analyst ratings summary and ratings history on Global Blood Therapeutics click here. For more ratings news on Global Blood Therapeutics click here.

Shares of Global Blood Therapeutics closed at $22.15 yesterday.

You May Also Be Interested In

• Watts Waters (WTS) PT Raised at TD Cowen; 'Shares May Be Ahead Of Themselves, But The Idea Makes Sense'
• Baker Hughes (BKR) PT Raised to $77 at TD Cowen
• BNP Paribas Exane Upgrades Novonesis A/S (NSISB:DC) to Neutral